Ghent – Pronota NV, a biomarker specialist firm that is based in Belgium, has launched its protein biomarker verification platform MASSterclass™. Pronota says that the novel antibody-free system will help to reduce the cost and time associated with quantitative assay development for screening low abundance biomarkers in the blood of patients. The technology uses a series of orthogonal complexity reduction steps that are combined with targeted tandem mass spectrometry. The new platform complements Pronota’s proprietary biomarker discovery platform, which generates a list of low-abundance protein biomarkers in blood. By combining the technologies, the firm believes that it can increase the chance of taking a biomarker from discovery all the way through to the clinic.